Zobrazeno 1 - 10 of 41 pro vyhledávání: '"E. D. Gomperts"'
1
F8haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
Autor: J, Schwarz, J, Astermark, E D, Menius, M, Carrington, S M, Donfield, E D, Gomperts, G W, Nelson, J, Oldenburg, A, Pavlova, A D, Shapiro, C A, Winkler, E, Berntorp, Dragan, Micic
Publikováno v: Haemophilia. 19:113-118
Ancestral background, specifically African descent, confers higher risk for development of inhibitory antibodies to factor VIII (FVIII) in haemophilia A. It has been suggested that differences in the distribution of FVIII gene (F8) haplotypes, and mi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8092a6f571851d79b81de9e391022da
https://doi.org/10.1111/hae.12004
Zobrazit plný text záznamu
2
The Effect of Vitamin E on Haemolysis in Paroxysmal Nocturnal Haemoglobinuria: In vitro and in vivo Studies
Autor: Diane Christensen, Jack Metz, S. S. Zail, E. D. Gomperts
Publikováno v: Scandinavian Journal of Haematology. 14:81-85
The administration of vitamin E, a natural antioxidant, to a patient with paroxysmal nocturnal haemoglobinuria (PNH) failed to diminish the urinary excretion of 59-Fe as monitored by 59-Fe whole body counting and urinary loss of isotope. However, in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74d0a01f8972679174e8eec4cd667e2a
https://doi.org/10.1111/j.1600-0609.1975.tb00299.x
Zobrazit plný text záznamu
3
A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A
Autor: G L Bray, G C White nd, S Courter, M Lee, E D Gomperts
Publikováno v: Thrombosis and Haemostasis. 77:660-667
SummaryA prospective, open-label multicenter investigation has been conducted to compare pharmacokinetic parameters of recombinant DNA-derived FVIII (rFVIII) and plasma-derived FVIII concentrate (pdFVIII) and to assess safety and efficacy of long-ter
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a1fad789348236bc8f96a615f4381574
https://doi.org/10.1055/s-0038-1656030
Zobrazit plný text záznamu
5
Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events
Autor: H J, Ehrlich, M J, Henzl, E D, Gomperts
Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia. 8(2)
Published and unpublished spontaneously reported thrombotic adverse events (AEs) in factor VIII inhibitor bypass activity (FEIBA(R)) recipients were compiled for the most recent 10-year period during which FEIBA(R) units equivalent to 3.95 x 105 typi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2862c67b873be7946b48e127fcadc290
https://pubmed.ncbi.nlm.nih.gov/11952842
Zobrazit plný text záznamu
6
Prevalence and incidence of intracranial haemorrhage in a population of children with haemophilia. The Hemophilia Growth and Development Study
Autor: M D, Nelson, M A, Maeder, D, Usner, W G, Mitchell, M J, Fenstermacher, D A, Wilson, E D, Gomperts
Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia. 5(5)
The prevalence of intracranial haemorrhage (ICH) in our population of haemophiliacs was 12%. The incidence of ICH was approximately 2% per year. At entry, 7% (21/309) had clinical histories of ICH without MRI evidence of old haemorrhage, indicating t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::248819c7947f6333beb45569650607e9
https://pubmed.ncbi.nlm.nih.gov/10583511
Zobrazit plný text záznamu
7
A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group
Autor: G L, Bray, E D, Gomperts, S, Courter, R, Gruppo, E M, Gordon, M, Manco-Johnson, A, Shapiro, E, Scheibel, G, White, M, Lee
Publikováno v: Blood. 83(9)
In July 1990, the Recombinate Study Group initiated a prospective, open-labeled investigation of recombinant factor VIII (r-FVIII) to assess its safety and efficacy and to characterize the natural history of inhibitor development in previously untrea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::12a40ad0c11d8fa9183b5748e01f52de
https://pubmed.ncbi.nlm.nih.gov/8167332
Zobrazit plný text záznamu
8
Immune and serologic profiles of HIV-infected and noninfected hemophilic children and adolescents. Hemophilia Growth and Development Study Group
Autor: J, Jason, J, Murphy, L A, Sleeper, S M, Donfield, I, Warrier, S, Arkin, B, Evatt, E D, Gomperts
Publikováno v: American journal of hematology. 46(1)
To assess relationships among the effects of HIV on hemophilic children and adolescents' immunologic parameters and vaccine-related serology.We analyzed data from extensive baseline immunologic evaluations of 207 HIV antibody-positive (HIV+) and 126
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7575106f527d244ae3969474f6642a0a
https://pubmed.ncbi.nlm.nih.gov/8184874
Zobrazit plný text záznamu
9
A clinical evaluation of genetic stability
Autor: E D, Gomperts, S G, Courter, M D, Lynes, D A, Baker
Publikováno v: Developments in biological standardization. 83
Mutation in a genetically engineered cell line has not been shown to have been responsible for adverse clinical reactions in a currently licensed biotechnology product. There exists, however, the theoretical possibility that mutations in the producti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4dc4b9f551b3104a73c071b6b021162e
https://pubmed.ncbi.nlm.nih.gov/7883084
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje